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The classical magic bullets
The discovery of antibiotics, pioneered by personalities like Paul Ehrlich, Selman Waksman and Alexander Fleming,
ushered in a new era of infection medicine. In the year 1900, Paul Ehrlich first described the concept of the ‘magic
bullet’, a chemical that harms pathogens but not the host. The first successful ‘magic bullet’ was arsphenamine,
which revolutionized the treatment of syphilis [1]. The serendipitous discovery of penicillin by Fleming in 1928 and
the isolation of streptomycin and other antibiotics from soil bacteria by Waksman in the 1940s heralded the golden
age of antibiotics. Since then, a plethora of antimicrobial substances have been identified and made available for
medical use [2].
Penicillin impairs the synthesis of the bacterial cell wall and streptomycin inhibits ribosome function. Until
today, these two processes are still the most common targets of clinically used antibiotics. However, there are
many other known mechanisms of action of antibiotics and a variety of bacterial cell structures can be exploited as
antibiotic targets. This includes, for example, the cell membrane, DNA, RNA or specific enzymes. Understanding
the mechanisms underlying antibacterial activity is essential for efficient drug development and identifying its
molecular target is a prerequisite for bringing a new drug to the market.
A new era of drug development
Today, the golden age of antibiotics has passed and the increasing resistance of bacteria to established antibiotic
classes demands creative antibacterial solutions. Thus, drug candidates with not yet clinically exploited targets are
favorable over derivatives of existing drugs. However, this approach no longer allows for straightforward target
validation with established standard assays. Moreover, it has become abundantly clear that antibiotics with specific
protein targets suffer from fast resistance development rates. For example, sulfonamides, targeting an enzyme
involved in folate synthesis and rifampicin, targeting RNA polymerase, are famous for fast resistance development
and are therefore applied in combination with other drugs [3,4]. In search of more durable solutions, antibiotic lead
development has gradually shifted to antibiotic candidates with targets encoded by multiple genes, with structural or
multiple targets [5].
Despite many successful antibiotic classes falling into this category [5], antibiotic drug development has had
a strong focus on single-target antibiotic candidates for a considerable time. It has long been a common notion
that only highly specific single-target drugs provide the required selectivity and therapeutic window to be used in
patients with acceptable side effects. Multitarget drugs or compounds with structural targets, such as the cytoplasmic
membrane, have long been regarded unspecific and likely to display off-target activity in humans. Indeed, some
drugs with multiple and/or structural targets display serious side effects. Thus, polymyxins, which target both the
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outer and inner membrane of Gram-negative bacteria [6], may display severe nephrotoxicity and neurotoxicity [7].
However, other drugs with truly unspecific targets, such as nitrofurantoin, have been in clinical use for decades with
manageable side effects and severe adverse reactions are rare [8]. Nitrofurantoin is a prodrug that upon activation
by cellular reductases leads to the formation of reactive oxygen species, which damage cellular macromolecules
such as DNA, proteins and lipids [8]. While both human and bacterial reductases activate nitrofurantoin, this
process is much faster in bacteria, underlying its selectivity. Importantly, resistance against nitrofurantoin remains
rare despite its decade-long use in treating urinary tract infections [8]. On the other hand, compounds with only
one highly specific target in bacteria can still have off-target activity in humans and cause severe side effects or
allergic reactions. Examples include the high incidence of severe nephrotoxicity and ototoxicity observed for many
aminoglycosides and wide-spread allergies toward penicillins [9–11]. Moreover, several studies support the notion
that the most effective antibiotics that we use in the clinic do, in fact, not target a single molecule but affect multiple
processes in the bacterial cell [5,12].
These examples illustrate that the notion that single-target antibiotics are generally less toxic, must be abandoned.
At the same time, it is clear that potential off-target activity of any antibiotic drug candidate needs to be carefully
addressed. However, adverse effects observed in cell cultures or animal studies may vary significantly depending on
the model used. For example, the antibiotic candidate rhodomyrtone is toxic to zebrafish when administered orally,
but appears to be safe for oral consumption by humans [13]. Such host-dependent toxicity significantly complicates
the preclinical assessment of antibiotic off-target activity.
Despite the pitfall of potentially increased toxicity, the rapid development of antimicrobial resistance has led
to a re-evaluation of antibiotic drug candidates with structural and multiple targets that were previously regarded
unspecific.
Complex & multiple mechanisms of action
Some mechanisms of action presuppose multiple targets or at least multiple effects. For example, bacitracin binds
to bactoprenol phosphate and affects both synthesis of cell wall peptidoglycan and cell wall teichoic acids, since
both pathways share bactoprenol phosphate as a transmembrane carrier molecule for their respective precursors [14].
Membrane-active antibiotics, although possibly binding to only a single target, by default inhibit multiple cellular
processes. Their interference with membrane functionality primarily impairs cell wall synthesis and cellular respira-
tion, but also a multitude of other membrane-bound processes such as cell division, protein secretion, sporulation,
or the synthesis of new membrane material [12]. Some antibiotics bind to two or more separate molecular targets. For
example, polymyxins inhibit both the outer and inner membrane of Gram-negative bacteria [6] and the lantibiotic
nisin inhibits cell wall biosynthesis by binding to lipid II and subsequently uses the undecaprenyl-coupled cell wall
precursor as a docking molecule to form a transmembrane pore [15]. Nisin is also able to bind the intermediate lipid
I adding another molecule to its target repertoire [16].
Interestingly, nisin also displays a two-staged mechanism of action: it selectively inhibits cell wall synthesis at low
doses while pore formation requires a certain threshold concentration [17]. Similar concentration-dependent mode
of action shifts have been observed for several antimicrobial compounds. For example, both the fatty acid synthesis
inhibitor triclosan and the tetracycline-class ribosome inhibitor chelocardin additionally target the cytoplasmic
membrane at higher concentrations [18–20]. Such dose-dependent dual mechanisms add another layer of complexity
to the mechanistic diversity of antibiotic molecules.
While their advantages for resistance development are clear, the complex mechanisms of such drugs can be
hard to fully elucidate. One prominent example is the lipopeptide antibiotic daptomycin, which, based on model
membrane studies, was long believed to form pores in bacterial membranes [21]. This model was challenged, when
it was discovered that daptomycin does not cause pores in bacteria but instead interferes with membrane domains
that harbor the cell wall synthesis machinery [22]. A very recent study has now found that daptomycin is in fact a
dual target antibiotic and binds both phosphatidylglycerol-containing membrane lipids and undecaprenyl-coupled
cell wall precursors [23].
While the mechanisms of daptomycin has been elusive for a long time, surprising new activities are also being
discovered for antibiotics that were assumed to be well characterized and already fully understood. For example, it
was recently shown that the translation inhibitor tetracycline targets the bacterial cell membrane in addition to the
ribosome and that this appears to be a common feature of the tetracycline class of antibiotics [20,24]. These examples
illustrate how difficult it can be to fully understand antibiotic modes of action and it is well possible that other
established antibiotics have different or secondary mechanisms that have so far escaped discovery.
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Consequences for mode of action studies
While compounds with multiple mechanisms have the promise to be superior to single-target drugs in terms of
resistance development, they pose different challenges for the drug development process. Thus, such compounds
are often poorly characterized and tools to appropriately analyze their complex mechanisms of action may be
limited. Not only drug development, but also mode of action analysis has long been focused on single targets and
target validation has often been performed in vitro, for example, with isolated enzymes, isolated cell wall precursors,
or model membranes. Additionally, the decades-long focus of the pharmaceutical industry on single-target drugs
fostered a mindset of settling for one mechanism of action, since additional targets were viewed as unspecific off-
target activity. Thus, one major difficulty has long been the limited availability of suitable assays to study complex
antibiotic mechanisms in living bacterial cells. However, there is increasing evidence that mechanisms of action can
differ substantially between in vitro and in vivo and that antibiotics may have additional mechanisms of action in
living bacterial cells [12]. Thus, technologies to study antibiotic mechanisms in living bacteria are urgently needed
to capture their true nature and complexity.
While the realization that successful antibiotics do have more than one single target has emerged rather slowly, the
negative attitude toward multitarget antibiotics finally changed with the dramatic increase in drug-resistant bacteria.
Modern drug development may now even aim at multiple mechanisms and no longer shies away from complex
structural targets like the cell membrane. For example, the vancomycin derivatives telavancin and oritavancin carry
a lipid tail, which allows them to interact with the cytoplasmic membrane in addition to binding lipid II [25].
With this newly found appreciation for complex and multiple targets the range of advanced in vivo techniques
for mode of action analysis has increased as well. In particular, a range of cell biological tools to analyze complex
structural targets like the cytoplasmic membrane or cell wall components have been developed and employed for
antibiotic mode of action analysis with great success [22,26,27]. For example, the development of fluorescent amino
acids to visualize active cell wall synthesis and the application of specialized lipid dyes to analyze membrane domain
structure and fluidity now allow examining cellular processes that were not possible to observe in living bacteria
before [22,27]. These developments now make it possible to analyze how antibiotics interact with bacterial cell
structures and kill bacteria in impressive detail [13]. This cell biological toolbox is constantly expanding and new
tools for fluorescence and high-resolution microscopy are being developed, hopefully allowing even more detailed
insight into bacterial cell biology and antibiotic-killing mechanisms.
While it is a great advancement to microscopically observe bacterial cellular processes in real time, one perspective
alone rarely elucidates the whole picture, especially not when it comes to something as complex as the interactions
of antibiotic molecules with bacterial cells. Detailed in vivo approaches are the strongest, when combined with com-
plementary techniques. Thus, the combination with systems biology approaches, such as genomics, proteomics or
metabolomics, cutting-edge in vitro technologies, or molecular modeling have all been proven very successful in
unraveling the details of complex antibiotic mechanisms [13,28,29].
Several novel fields are emerging in and around antibiotic research, from new strategies to discover antimicrobial
compounds and new techniques to analyze them to approaches to resensitize bacteria to existing antibiotics and
developing antibiotic alternatives, the recent surge in antimicrobial resistance research has inspired many exciting
new approaches. For example, artificial intelligence and machine learning approaches have delivered the first
antibiotic candidates [30–33] and the potential of the microbiome in fighting bacterial infections is just being
discovered [34]. Likewise, novel inspiring tools for mode of action analysis are being developed, for example machine
learning approaches, new cell biological tools, or new image analysis platforms [35–37].
Whatever exciting new discoveries the future of antimicrobial drug development holds, one thing has become
abundantly clear, namely that different disciplines must join forces to truly understand all aspects of antibiotic
action that are relevant for drug discovery. Only if we understand how antibiotics really work, will we be able to
efficiently develop novel lead structures that have the potential to become more sustainable antibiotics than the
single-target screening hits resulting from the genomics-driven approaches that have dominated the landscape of
antibiotic hit discovery for the last decades.
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